Clinical Characteristics of Whole Patient Sample
| Characteristic | All patients with suspected ATTR-CM (n = 144) | Patients with preserved LVEF (≥50%, n = 98) | Patients with impaired LVEF (<50%, n = 46) | P |
|---|---|---|---|---|
| Clinical parameters | ||||
| BMI (kg/m2) | 26.4 ± 4.8 | 26.7 ± 4.4 | 25.1 ± 5.4 | 0.01* |
| NYHA functional class ≥ III | 38 (26.4%) | 24 (24.5%) | 14 (30.4%) | 0.29 |
| Age (y) | 81.5 ± 5.8 | 80.2 ± 8.2 | 79.7 ± 7.5 | 0.39 |
| Male sex | 127 (88.2%) | 87 (88.8%) | 40 (86.7%) | 0.34 |
| Laboratory parameters | ||||
| T-troponin (ng/L) | 42 (37) | 51.8 ± 39.5 | 60.0 ± 44.9 | 0.18 |
| Median nT-proBNP (pg/mL) | 2,294 (IQR, 3,368) | 1,540.0 (IQR, 3,193.0) | 2,925.0 (IQR, 2,452.0) | 0.01* |
| Median creatinine-phosphokinase (IU/L) | 88 (IQR, 73) | 88.0 (IQR, 80.0) | 104.4 (IQR, 67.0) | 0.68 |
| Echocardiographic parameters | ||||
| LVEDD (mm) | 45.8 ± 7.0 | 44.7 ± 6.9 | 48.7 ± 6.3 | 0.01* |
| LVEF (%) | 53.3 ± 10.8 | 58.8 ± 5.9 | 39.3 ± 7.2 | <0.001* |
| Maximum wall thickness (mm) | 15.9 ± 4.6 | 15.6 ± 3.1 | 16.5 ± 7.1 | 0.51 |
| Left ventricular mass index (g/m2) | 138.13 ± 52.6 | 131.1 ± 41.0 | 156.9 ± 71.8 | 0.09 |
| Scintigraphy | ||||
| Perugini score 0 | 43 (29.9%) | 29 (29.6%) | 14 (30.4%) | 0.43 |
| Perugini score 1 | 9 (6.3%) | 6 (6.1%) | 3 (6.5%) | 0.60 |
| Perugini score 2 | 65 (45.1%) | 48 (49.0%) | 17 (37.0%) | 0.18 |
| Perugini score 3 | 27 (18.8%) | 16 (16.3%) | 11 (23.9%) | 0.19 |
| SUVmax | 9.3 ± 6.7 | 9.9 ± 7.0 | 7.9 ± 5.9 | 0.18 |
| SUVpeak | 8.7 ± 6.3 | 9.2 ± 6.6 | 7.3 ± 5.5 | 0.17 |
| Therapy | ||||
| Ace inhibitors | 36 (25.0%) | 28 (28.6%) | 8 (17.4%) | 0.28 |
| Angiotensin-II inhibitors | 49 (34.0%) | 36 (36.7%) | 13 (28.3%) | 0.51 |
| Sacubitril/valsartan | 3 (2.1%) | 1 (1.0%) | 2 (4.3%) | 0.18 |
| β-blockers | 63 (43.8%) | 36 (36.7%) | 27 (58.7%) | <0.001* |
| Spironolactone | 21 (14.6%) | 11 (11.2%) | 10 (2.2%) | 0.03* |
| SGLT-2 inhibitors | 19 (13.2%) | 8 (8.2%) | 11 (23.9%) | 0.003* |
| Diuretics | 86 (39.7%) | 60 (61.2%) | 26 (56.5%) | 0.22 |
| Calcium channels antagonists | 32 (22.2%) | 28 (28.6%) | 4 (8.6%) | 0.02* |
| Amiodaron | 8 (5.6%) | 5 (5.1%) | 3 (6.5%) | 0.38 |
| Tafamidis | 53 (36.8%) | 38 (38.8%) | 15 (32.6%) | 0.30 |
↵* Statistically significant.
NYHA = New York Heart Association.
Qualitative data are number and percentage; continuous data are mean ± SD unless otherwise indicated. Therapies other than transthyretin stabilizer were recorded at baseline; therapy with tafamidis (if any) was started after final diagnosis was reached.